Linoforce granules

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Rhamnus frangula l., cortex (frangula bark, commimnuted); Cassia senna l. and/or cassia angustifolia vahl, folium (senna leaves, comminuted); Linum usitatissimum l., semen (linseeds, whole)

Available from:

Bioforce (UK) Ltd

ATC code:

A06AB

INN (International Name):

Rhamnus frangula l., cortex (frangula bark, commimnuted); Cassia senna l. and/or cassia angustifolia vahl, folium (senna leaves, comminuted); Linum usitatissimum l., semen (linseeds, whole)

Dosage:

.

Pharmaceutical form:

Granules

Prescription type:

Product not subject to medical prescription

Therapeutic area:

Contact laxatives

Authorization status:

Authorised

Authorization date:

2014-05-09

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Linoforce granules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose [4.1 g] (one level measuring spoon) contains:
1.76 g of_ Linum usitatissimum_ L., semen (Linseeds, whole),
0.43 - 0.70 g of_ Cassia senna_ L. and/or_ Cassia angustifolia_ Vahl,
folium (Senna leaves, comminuted)
36 - 58 mg of_ Rhamnus frangula_ L., cortex (Frangula bark,
comminuted),
corresponding to 20.5 mg of hydroxyanthracene derivatives, calculated
as sennoside B.
Excipient with known effect:
One dose (4.1g) contains 480 mg sucrose
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Granules
Linoforce is a glossy granulate of dark brown colour with an odour of
vanillin and a sweetish taste.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Traditional herbal medicinal product for the short term relief of
occasional constipation exclusively based on long-
standing use.
This product is indicated for use in adults and adolescents over 12
years.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
Adults, older people and adolescents over 12 years: One level
measuring spoon (4.1g), administered in a single dose at
night with a glass of water or other liquid.
The recommended dose is equivalent to 20.5 mg of hydroxyanthracene
derivatives expressed as sennoside B. The use
in children under 12 years of age is contraindicated (see section 4.3
Contraindications).
DURATION OF USE
If condition worsens or symptoms persist during the use of Linoforce
or for more than 1 week, a doctor should be
consulted.
Prolonged continuous use is not recommended.
METHOD OF ADMINISTRATION
For oral use only.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_